sorafenib has been researched along with sb 225002 in 2 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (sb 225002) | Trials (sb 225002) | Recent Studies (post-2010) (sb 225002) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 92 | 0 | 73 |
| Protein | Taxonomy | sorafenib (IC50) | sb 225002 (IC50) |
|---|---|---|---|
| C-X-C chemokine receptor type 1 | Homo sapiens (human) | 0.022 | |
| C-X-C chemokine receptor type 2 | Homo sapiens (human) | 0.0623 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chu, B; Jiang, Y; Li, Q; Liu, Z; Luo, J; Shi, Z; Xin, Q; Ye, L; Zhan, F; Zhang, X; Zhu, Q | 1 |
| Devapatla, B; Sharma, A; Woo, S | 1 |
2 other study(ies) available for sorafenib and sb 225002
| Article | Year |
|---|---|
Design, synthesis and anti-tumor evaluation of 1,2,4-triazol-3-one derivatives and pyridazinone derivatives as novel CXCR2 antagonists.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Pyridazines; Receptors, Interleukin-8B; Structure-Activity Relationship; Triazoles | 2021 |
CXCR2 Inhibition Combined with Sorafenib Improved Antitumor and Antiangiogenic Response in Preclinical Models of Ovarian Cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Disease Models, Animal; Disease Progression; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Human Umbilical Vein Endothelial Cells; Mice, Nude; Neovascularization, Pathologic; Niacinamide; Ovarian Neoplasms; Phenotype; Phenylurea Compounds; Receptors, Interleukin-8B; Sorafenib; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2015 |